Filing Flows › Tarsus Pharmaceuticals (TARS) › Capital expenditures
Tarsus Pharmaceuticals (TARS) capital expenditures by quarter
Tarsus Pharmaceuticals' capital expenditures were $4.1M in Q2 2026 (second quarter 2026), -36% from Q4 2025. Over the last 3 quarters it ranged from $1.9M (Q3 2025) to $6.4M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.1M | -36% | — |
| Q4 2025 | $6.4M | +233% | — |
| Q3 2025 | $1.9M | — | — |
Q2 2026 at a glance
Tarsus Pharmaceuticals, Q2 2026: revenue $174M (+69% year over year), operating margin -11.4%, net loss $18.6M, operating cash flow $61.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tarsus Pharmaceuticals' capital expenditures?
Tarsus Pharmaceuticals' capital expenditures were $4.1M in Q2 2026 (second quarter 2026), -36% from Q4 2025.
How has Tarsus Pharmaceuticals' capital expenditures changed?
Over the last 3 quarters it ranged from $1.9M (Q3 2025) to $6.4M (Q4 2025).
Q2 2026 results → · How Tarsus Pharmaceuticals makes money →